Clinical performance characteristics of the adiana® system for permanent contraception: the first year of commercial use.

In 2009, the Adiana® System for Permanent Contraception was approved by the US Food and Drug Administration and became the second device on the market for hysteroscopic sterilization. This article outlines the basics of the Adiana procedure as it relates to the initial 12-month clinical experience following commercial launch. Safety, efficacy, and practical applications are explored to provide a better understanding of product performance characteristics in the first year of actual clinical use.

Prophylactic antibiotics for non-laboring patients with intact membranes undergoing cesarean delivery: an economic analysis.

Objective: We conducted an economic analysis of prophylactic antibiotic administration for elective cesarean delivery.

Study Design: We created a decision tree comparing the use of prophylactic antibiotics (cefazolin 1 gm intravenous) with no antibiotic use. We modeled the potential for anaphylaxis, and included outcomes of fever and endometritis.